Navigation Links
Genta Initiates Phase 3 AGENDA Trial of Genasense(R) for Patients with Advanced Melanoma
Date:8/21/2007

Randomized, Double-Blind Study Targets Biomarker-Defined Population

BERKELEY HEIGHTS, N.J., Aug. 21 /PRNewswire-FirstCall/ -- Genta Incorporated (Nasdaq: GNTA) announced that the first patients have been enrolled in the Company's confirmatory Phase 3 trial of Genasense (oblimersen sodium) Injection in advanced melanoma. The trial, known as AGENDA, is a randomized, double-blind, placebo-controlled study in which patients are randomly assigned to receive Genasense plus dacarbazine (DTIC) or DTIC alone. AGENDA will accrue approximately 300 patients and will be conducted at approximately 100 sites worldwide, including North America, Europe and Australia. Accrual is expected to take approximately 18 months, with initial data expected shortly thereafter.

AGENDA is designed to confirm the safety and efficacy of Genasense when combined with DTIC in patients who have not previously received chemotherapy. Genta's prior Phase 3 trial of this drug combination had shown that maximal benefit occurred in patients with normal baseline LDH, a blood enzyme that strongly correlates with outcome. The AGENDA study is limited to patients whose baseline LDH is less than 0.8 times the upper limit of normal. Analysis of that trial suggested that patients in this group achieved a significantly superior outcome (see table below).

"Genasense plus dacarbazine yielded superior results in a large randomized trial," said Dr. Agop Bedikian, Professor of Medicine at the M.D. Anderson Cancer Center, Houston, TX, who was the lead author on the publication of the previous Genasense trial. "Our center is pleased to have entered the first patient onto this important new study that seeks to extend those initial results using a biomarker t
'/>"/>

SOURCE Genta Incorporated

Copyright©2007 PR Newswire.

2

GOOD

Page: 1 2 3 4 5

Related medicine technology :

1. Genta Announces Results of Phase 1 Study Using Genasense Administered by Intermittent Subcutaneous Injection
2. Genta Incorporated to Present Multiple Abstracts at the Annual Meeting of the American Society of Clinical Oncology
3. Malvern initiates European user group meetings for chemical imaging
4. Data Available From Erbitux Phase III Study in First-Line Treatment of Advanced Lung Cancer
5. Phase 3 Results for Dabigatran Etexilate, an Investigational Oral Anticoagulant, Presented Today at the XXIst Congress of the International Society on Thrombosis and Haemostasis
6. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
7. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
8. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
9. Actemra (tocilizumab) Third Phase III Study Results Show Significant Improvement in Symptoms of Patients with Rheumatoid Arthritis
10. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
11. NexMed Announces Completion of Patient Enrollment in Two Pivotal Phase 3 Studies for Anti-Fungal Product
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/12/2010)... and creativity. History has produced a legion of great nappers. Among them are Leonardo Da Vinci , Thomas Edison and Lord Byron, who ... ... , ... ... ...
(Date:3/12/2010)... ADVENTRX Pharmaceuticals, Inc. (NYSE Amex: ANX ) today announced that the U.S. Food and Drug Administration (FDA) has accepted the proposed proprietary name "Exelbine™" ... ... , ... ... ...
(Date:3/11/2010)... Inc. (Nasdaq: NXTM ) a leading manufacturer of innovative dialysis products, today announced that it has secured a two-year $15 million revolving ... ... , ... ... ...
Breaking Medicine Technology:Protect-A-Bed(R) Supports the Art of Napping on National Napping Day 2Protect-A-Bed(R) Supports the Art of Napping on National Napping Day 3Protect-A-Bed(R) Supports the Art of Napping on National Napping Day 4ADVENTRX Receives Brand Name Acceptance for ANX-530 2ADVENTRX Receives Brand Name Acceptance for ANX-530 3ADVENTRX Receives Brand Name Acceptance for ANX-530 4NxStage(R) Secures $15 Million Revolving Line of Credit 2NxStage(R) Secures $15 Million Revolving Line of Credit 3NxStage(R) Secures $15 Million Revolving Line of Credit 4UCSF Scientist Receives Nobel Prize in Physiology or Medicine 58851 1UCSF Scientist Receives Nobel Prize in Physiology or Medicine 58851 2UCSF Scientist Receives Nobel Prize in Physiology or Medicine 58851 3UCSF Scientist Receives Nobel Prize in Physiology or Medicine 58851 4Wonderful 28R 29 Pistachios Invites America to 26quot 3BGet Crackin 26quot 3B 58847 1Wonderful 28R 29 Pistachios Invites America to 26quot 3BGet Crackin 26quot 3B 58847 2Wonderful 28R 29 Pistachios Invites America to 26quot 3BGet Crackin 26quot 3B 58847 3Wonderful 28R 29 Pistachios Invites America to 26quot 3BGet Crackin 26quot 3B 58847 4 R E P E A T DiagnoCure signs distribution agreement in the UK for its colorectal cancer test 58843 1 R E P E A T DiagnoCure signs distribution agreement in the UK for its colorectal cancer test 58843 2 R E P E A T DiagnoCure signs distribution agreement in the UK for its colorectal cancer test 58843 3
... Lexicon,Pharmaceuticals, Inc. (Nasdaq: LXRX ) announced today ... application to the U.S. Food and Drug,Administration (FDA) ... and other autoimmune conditions. The initial Phase 1 ... randomized,placebo-controlled, ascending single-dose study in healthy volunteers,designed to ...
... Symptoms, DALLAS, Nov. 11 Veramyst(TM) (fluticasone ... of nasal,and ocular allergy symptoms of perennial allergic ... older, according to a clinical study presented,today at ... of Allergy,Asthma & Immunology (ACAAI). Perennial allergic ...
Other Medicine Technology:Lexicon Files Investigational New Drug Application for LX2931 as a Potential Treatment for Rheumatoid Arthritis 2Lexicon Files Investigational New Drug Application for LX2931 as a Potential Treatment for Rheumatoid Arthritis 3New Data Shows Veramyst Effectively Treats Symptoms of Perennial Allergic Rhinitis 2New Data Shows Veramyst Effectively Treats Symptoms of Perennial Allergic Rhinitis 3New Data Shows Veramyst Effectively Treats Symptoms of Perennial Allergic Rhinitis 4
(Date:3/13/2010)... during Save Your Vision month , , SATURDAY, March ... injuries cost the American economy billions each year ... problems could be prevented with simple measures, such ... protective eyewear, experts say. , "Healthy vision is ... director of the Vision Ergonomics Laboratory at the ...
(Date:3/13/2010)... /PRNewswire-Asia/ -- Moleac Pte Ltd has been granted,the Emerging Company of the Year 2010 ... Asia Pacific .,This award recognizes Moleac,s innovative business model; its contribution to,local community ... to emerge as a major success,within the next three to five years. , ... ... ...
(Date:3/13/2010)... the 11th annual Zone Cruise to beautiful Caribbean vacation spots, and ... prepared according to standard Zone recipes. , ... Fort ... health, devotees of the globally popular Zone diet are ... Zone diet creator and best selling author of The Zone, on ...
(Date:3/13/2010)... knee (anterior cruciate ligament) reconstruction with a patellar tendon ... of the tibia or shin bone) graft continue at ... to a study presented today at the American Orthopaedic ... Louisiana (March 13). Additionally, these patients have not developed ... have done this procedure for many years and this ...
(Date:3/12/2010)... Though consumers have slowed frivolous spending habits, ... things that make their daily life easier. Saving time is ... why Laser Hair Removal treatments are growing increasingly ... that laser hair removal saves a tremendous amount ... lasts for years, even a lifetime. Unlike waxing, plucking, shaving ...
Breaking Medicine News(10 mins):Health News:Eye Health and Safety Should Be Job One 2Health News:Moleac Receives BioSpectrum Asia Emerging Company of the Year 2010 Award 2Health News:Moleac Receives BioSpectrum Asia Emerging Company of the Year 2010 Award 3Health News:Moleac Receives BioSpectrum Asia Emerging Company of the Year 2010 Award 4Health News:Moleac Receives BioSpectrum Asia Emerging Company of the Year 2010 Award 5Health News:Moleac Receives BioSpectrum Asia Emerging Company of the Year 2010 Award 6Health News:Zone Diet Devotees Set Sail with Dr. Barry Sears on Zone Cruise to Better Health 2Health News:15 years after ACL knee reconstruction, 84 percent of male patients still highly active, study says 2Health News:Ring In the New Year With a Beautiful, Smooth Body 2Health News:Ring In the New Year With a Beautiful, Smooth Body 3
... 5 year old boy in Thailand which has raised the toll ... in direct contact with chickens, but the officials feel// that he ... ,The latest good news to ease bird flu fear has come ... has given permission to manufacturers to produce generic version of Tamiflu, ...
... for some overweight people—they cannot reduce weight by exercise ... obese patients often prescribe exercise as part of a ... led by psychologist Rona Levy at the University of ... may be hampered by a variety of gastrointestinal problems ...
... cancer should not be a stimulation to be relieved ... infection//. ,This arises due to its treatment ... with the general population. ,According to the study ... colorectal cancer, lung cancer, renal cancer, thyroid cancer, soft ...
... professor of neurology at the University of California who ... stroke has highlighted that more than// 32,000 neurons (brain ... episode of stroke. In addition, nearly 14 billion synapses ... 7.5 miles are lost in just a single minute ...
... The increasing number of people resorting to sleeping pills for ... more effective medications. However, they may not have the best ... ,The importance of sleep can be inferred form ... man healthy, wealthy and wise’. For those of them who ...
... The chances of the babies falling a victim to cot ... a study which the British Medical Journal published. The babies ... smoke are particularly at risk where the Sudden Infant Death ... over 300 babies die due to SIDS every year. There ...
Other Medicine News:Health News:Stroke Destroys Nearly 32, 000 Neurons In Just A Second! 2Health News:Newer Generation Sleeping Pills Lack Superior Performance 2
Straight shafts with 0.12 mm teeth and tying platform. Serrated handle with polished finish....
Colibri style tips. Double toothed tips with 0.10 mm teeth spaced 1 mm apart and 7 mm tying platform. Wide serrated handle with polished finish....
Straight shafts with 1 x 2 teeth and serrated handle with polished finish....
Serrated, 10 mm tips angled 90 degrees. Serrated cross action handle with polished finish....
Medicine Products: